Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with (177)Lu-DOTATATE

BACKGROUND: Monitoring of pancreatic neuroendocrine tumors (PanNET) undergoing peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTATATE depends on changes in tumor size, which often occur late. Tumor growth rate (TGR) allows for quantitative assessment of the tumor kinetics expressed as %/...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Endocr Connect
Auteurs principaux: Pettersson, Olof Joakim, Fröss-Baron, Katarzyna, Crona, Joakim, Sundin, Anders
Format: Artigo
Langue:Inglês
Publié: Bioscientifica Ltd 2021
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8111309/
https://ncbi.nlm.nih.gov/pubmed/33875614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EC-21-0027
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires